baber/WOPTO huggingface dataset:
Patent NZ-539578-A (NZ)
Title: Health and performance status determination of a biological subject using level, abundance or functional activity of a gene expression product in sample cells
Inventor: BRANDON RICHARD BRUCE
IPC: G16H50/20
Filed: 2003-11-14
Abstract: A method of determining the status of a subject other than a human is disclosed. The subject data is obtained from cells in a biological sample of the subject. The subject data is from a single test and includes respective values for each of a number of parameters. The individual parameter values are representative of the level, abundance or functional activity of gene expression product in the cells and are indicative of the current biological status of the subject. The subject data is compared to predetermined data which includes values for at least some of the parameters and an indication of the condition. The status of the subject, and in particular, the presence and/or absence of the one or more conditions, can then be determined in accordance with the results of the comparison.
Patent NZ-540695-A (NZ)
Title: Novel heterocyclic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
Inventor: FRICK WENDELIN
IPC: C07H17/00
Filed: 2003-11-28
Abstract: Disclosed are fluoroglycoside derivatives of formula I wherein the substituents are as described in the specification. Compounds of the type disclosed are useful in lowering blood glucose and in preventing and treating type 1 and type 2 diabetes.
Patent NZ-541544-A (NZ)
Title: Benzimidazole derivatives and their use for modulating the GABAA receptor complex
Inventor: TEUBER LENE
IPC: A61P25/00
Filed: 2004-04-01
Abstract: Benzimidazole derivatives of formula (I) and pharmaceutical compositions containing these compounds are disclosed, wherein the variables are as defined in the specification. These compounds are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for combating anxiety and related diseases.
Patent NZ-541991-A (NZ)
Title: Ferric organic compounds, uses thereof and methods of making same
Inventor: KWOK DAVID W K
IPC: C07F15/02
Filed: 2004-02-18
Abstract: Disclosed is a method of synthesizing a form of ferric organic compound which comprises: a) obtaining a ferric iron salt; b) adding an alkaline metal hydroxide to the ferric iron salt at a rate and temperature effective to produce a uniform polyiron oxo suspension; c) isolating a precipitate from the suspension; d) adding an organic acid to the precipitate; e) forming a ferric-organic acid solution by heating the organic acid and the precipitate; and f) precipitating the form of ferric organic compound from the ferric-organic acid solution by adding an organic solvent to the solution.
Patent NZ-543945-A (NZ)
Title: Stackable skips
Inventor: TRACE JAMES CRISPIAN GARTH
IPC: B60P1/48
Filed: 2004-05-21
Abstract: A method of disposing of waste is disclosed. The method includes conveying two bins when at least one contains waste, on a load bed of a vehicle in as stacked manner. The bins are arranged one on top of another. The centre of the upper bin is positioned between a centre of the lower bin and the cab of the vehicle. Stackable bins for use in this method are also disclosed.
Patent NZ-546257-A (NZ)
Title: P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
Inventor: BANG KEUK CHAN
IPC: C07D401/12
Filed: 2004-10-06
Abstract: The disclosure relates to an effective p-glycoprotein inhibitor compound of formula (I) and a pharmaceutically acceptable salt thereof, a method for preparing the same and a pharmaceutical composition containing the same as an active ingredient. The bioavailability of an anticancer agent is enhanced when the anticancer agent is administered together with a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof by suppressing p-glycoprotein.
Patent NZ-548099-A (NZ)
Title: Novel fused pyrrolocarbazoles
Inventor: BECKNELL NADINE C
IPC: C07D487/04
Filed: 2004-12-23
Abstract: Disclosed is a compound of formula II wherein Q is CH2CH2 and the other substituents are disclosed within the specification or a stereoisomer or a salt thereof. Also disclosed is the use of the compound of formula II for treating prostate disorder, angiogenic disorder, pathological disorder, cancer of solid tumors and multiple myeloma or leukemia.
Patent NZ-548420-A (NZ)
Title: Novel phenylalanine derivative
Inventor: SAGI KAZUYUKI
IPC: C07D487/04
Filed: 2004-12-22
Abstract: Phenylalanine derivatives of the following formula (1) or pharmaceutically acceptable salts thereof wherein the substituents are disclosed in the specification. Also disclosed is An alpha 4 integrin antagonist comprising a phenylalanine derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
Patent NZ-550387-A (NZ)
Title: Recessed external corner flashing
Inventor: KENNEDY ANTHONY DAVID
Filed: 2006-10-09
Abstract: An outside corner flashing of a single length of material with six faces A to F and bent with five lengthwise parallel folds substantially as illustrated. Going around the section of the profile from one face to the next, A to B is bent 45 degrees in a first direction, B to C is bent 165 degrees in a second direction, C to D is bent between 90 and 135 degrees in the second direction, D to E is bent 165 degrees in the second direction, and E to F is bent 45 degrees in the first direction.
Patent NZ-552559-A (NZ)
Title: Solid preparation comprising an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like
Inventor: KOIKE MASAHIKO
IPC: A61K45/06
Filed: 2003-10-06
Abstract: Disclosed is a solid preparation containing an insulin sensitizer and an active ingredient (other than the insulin sensitizer) which is useful as a remedy for diabetes. It is uniform in the contents of the insulin sensitizing and the active ingredient. The active ingredient is preferably a biguanide (metformin hydrochloride). (62) Divided Out of 539711
Patent NZ-553028-A (NZ)
Title: Isoindoline compounds and methods of making and using the same
Inventor: MULLER GEORGE W
IPC: A61K31/4035
Filed: 2005-07-27
Abstract: Disclosed is a N-benzyl isoindoline derivative, or pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, as defined in the specification in particular, 3-(1,3-dioxobenzo[e]isoindolin-2-yl)-3-(-3-ethoxy-4-methoxyphenyl)propanenitrile, (1S)-Furan-2-carboxylic acid {2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3- dihydro-1H-isoindol-4-yl}-amide, (1S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2- methanesulfonyl-ethyl]-l ,3-dioxo-2,3-dihydro-lHisoindol-4-yl}-2-methoxy-acetamide, (1S)-7-(cyclopropylmethyl-amino)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-2,3-dihydro-isoindol-l-one, (1S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2methanesulfonyl-ethyl]-7-isobutylamino-2,3-dihydro-isoindol-1-one, (3R)-3-[7-(2,2-simethyl-propylamino)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(3-ethoxy-4methoxyphenyl)-N,N-dimethyl-propionamide, 3-(3-ethoxy-4-methoxy-phenyl)-3-(4-isobutylamino1,3-dioxo-l,3-dihydro-isoindol-2-yl)-propionitrile, N-{2-[cyano(3-ethoxy-4-methoxyphenyl)methyl]-1,3-dioxoisoindolin-4-yl}acetamide, N-{2-[Cyano(3-ethoxy-4-metboxyphenyl)methyl]1,3-dioxoisoindolin-4-yl}(benzylamino)carboxamide, N-{2-[cyano(3-cyclopentyloxy-4-methoxyphenyl)methyl]-1,3-dioxoisoindolin-4-yl}acetamide, amino-N-{2-[cyano(3-ethoxy-4-methoxyphenyl)methyl]-1,3-dioxoisoindolin-5yl}amide, amino-N-{2-[cyano(3-ethoxy-4methoxyphenyl)-methyl]-1,3-dioxoisoindolin-4yl}amide, N-{2-[1-(3-cyclopropylmethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide, cyclopropanecarboxylic acid {2-[1-(3-cyclopropylmethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide, (3R)-3(7-(3,3-dimethyl-ureido)-1-oxo-1,3-dihydro-isoindol-2-yl}-3-(3-ethoxy-4-methoxy-phenyl)-N,N-dimethylpropionamide and (1S)-3-{2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-1,1-dimethyl-urea wherein the pictured compounds are representative examples. Also disclosed is the use of the above compound for treating disorders affecting by PDE4 inhibition or the production of TNF-alpha e.g. cancer, depression and arthritis.
Patent NZ-574724-A (NZ)
Title: Association of single nucleotide polymorphisms, dairy form and productive life
Inventor: WOODWARD BRENT
IPC: G06F19/22
Filed: 2007-08-10
Abstract: Disclosed are single nucleotide polymorphisms (SNPs) within the bovine genes encoding leptin, corticotropin-releasing hormone (CRH), and mitochondrial transcription factor A (TFAM) and their association with the economically relevant traits of dairy form and productive life. The SNPs are used in methods and systems, including computer-assisted processes, for identifying bovine animals having a longer productive life and for tracking the productive life of a bovine animal.
Patent NZ-575831-A (NZ)
Title: Enantiomerically pure phosphoindoles as hiv inhibitors
Inventor: STORER RICHARD
IPC: A61K31/675
Filed: 2007-09-28
Abstract: Disclosed are enantiomerically pure compounds as represented by the general formula (C), wherein R3'' and R5'' are independently alkyl or alkenyl, wherein the alkenyl group may optionally be substituted with cyano; R2'', R4'' and R6'' are hydrogen; each of R4' and R5' is independently hydrogen or halogen; R6' and R7' are hydrogen; R1 is hydrogen or benzensulphonyl (S(O)2-Ph); Y is an alkoxy group; and Z is -CO2Et or -C(=O)NH2. Of particular importance are the compounds (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester and (2-carbamoyl-5-chloro-4-fluoro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a pharmaceutical carrier, excipient, or diluent; wherein said composition is substantially free of the opposite enantiomer of said compound; and the composition if for the treatment, prevention, amelioration or management of symptoms associated with an HIV infection in a subject.
Patent NZ-577390-A (NZ)
Title: Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
Inventor: TUITEN JAN JOHAN ADRIAAN
IPC: A61K31/519
Filed: 2007-11-02
Abstract: Provided is the use of testosterone and a 5-HT1A agonist in the preparation of a medicament for the treatment of sexual dysfunction, wherein said medicament is used on demand, wherein said 5-HT1A agonist is released essentially one hour before and said testosterone essentially 3.5-5.5 hours prior to sexual activity so that the peak effects of the 5-HT1A agonist and testosterone partly overlap, wherein said testosterone is provided as a short-lasting peak, and wherein the amount of testosterone is at most 2.5 mg.
Patent NZ-579263-A (NZ)
Title: Shielding means to be applied to data input apparatus to avoid unauthrozed viewing
Inventor: CLANCY PAUL
IPC: G06F21/83
Filed: 2008-03-07
Abstract: Disclosed is a shield means (402) that is provided for use on data input apparatus. The shield means (402) includes a housing (406) or frame with at least one channel. The at least one channel has a first end and a second end and is arranged such that a user can view the first channel end in a first position when the user is looking through the second channel end and the user's line of vision is substantially parallel with the longitudinal axis of said channel. This allows data and/or data input means associated with or below the first channel end to be viewed by the user in the first position. The view of the first channel end is substantially obscured or shielded from the user in at least a second position when the user's line of vision is at an acute angle to said channel longitudinal axis. The at least one channel protrudes outwardly from an upper surface (404) of the housing (406) or frame. The second channel end is a spaced distance above the upper surface (404) of the housing or frame.
Patent NZ-583282-A (NZ)
Title: Human c-fms antigen binding proteins
Inventor: BRASEL KENNETH ALLAN
IPC: A61K39/395
Filed: 2008-08-19
Abstract: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-I, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
Patent NZ-585434-A (NZ)
Title: Novel glucocorticoid receptor agonists
Inventor: MILLAN DAVID SIMON
IPC: A61K31/58
Filed: 2008-11-17
Abstract: Disclosed are 16a,17a-benzylidenedioxy-11b,21-dihydroxypregna-1,4-diene-3,20-dione derivatives as represented by the general formula (I), wherein: R1 is a benzyl, phenylthio or phenylthiomethyl moiety as defined herein. Of particular importance is the compound (4aS,4bR,5S,6aS,6bS,8R,9aR,10aS,10bS,12S)-8-(4-{ [(3-chloro-4-hydroxyphenyl)thio]methyl} phenyl)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one. Further disclosed is a pharmaceutical composition which comprises an effective amount of a compound as defined above, or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt, and one or more pharmaceutically acceptable excipients, for the treatment of one or more diseases, disorders and conditions selected from skin diseases; inflammatory conditions of the nose, throat and lungs (such as rhinitis, sinusitis, asthma, nasal polyps, chronic obstructive pulmonary disease (COPD) and fibrosis); inflammatory diseases of the intestine; auto-immune diseases; and ocular conditions.
Patent NZ-586431-A (NZ)
Title: Genetic variants on chr hq and 6q as markers for prostate and colorectal cancer predisposition
Inventor: GUDMUNDSSON JULIUS
IPC: G16H70/60
Filed: 2008-12-05
Abstract: Provided is a method of determining a susceptibility to prostate cancer, the method comprising determining in a patient nucleic acid sequence the presence of allele G in rs10896450, or a marker allele in linkage disequilibrium therewith, wherein linkage disequilibrium is characterized by numerical values of r2> 0.2, wherein the G allele is indicative of an increased susceptibility to prostate cancer.
Patent NZ-590827-A (NZ)
Title: A method for recovery of high purity carbon dioxide
Inventor: FIND RASMUS
IPC: C01B32/50
Filed: 2009-07-24
Abstract: Disclosed is a method for the removal of contaminants, including at least benzene, from a carbon dioxide feeding liquid stream, originating from a carbon dioxide feeding gas stream, comprising the steps of introducing the liquid stream into a flash column to provide a liquid stream and a carbon dioxide rich gaseous stream; separating the liquid obtained from the previous step into a carbon dioxide rich stripper off gas and a carbon dioxide-depleted liquid by means of stripping in a stripper column; and feeding a gaseous fraction of the carbon dioxide rich stripper off gas at the bottom of the flash column of step introduction step. Also disclosed is the use of a carbon dioxide enriched gas obtained in said method as a component in foodstuff hospital devices or in enhanced oil recovery or sequestration.
Patent NZ-594498-A (NZ)
Title: Waste traps and their componentry
Inventor: HAYNES ANDREW LEO
IPC: E03C1/122
Filed: 2011-08-09
Abstract: 594498 A nut for use in drain traps has a circumferential groove to serve as a guide to cut the nut into segments if it needs to be reduced in length.
Patent NZ-596660-A (NZ)
Title: Dig-5 insecticidal cry toxins
Inventor: LIRA JUSTIN
IPC: A01N63/50
Filed: 2010-06-14
Abstract: Patent No. 596660 Disclosed is an isolated polypeptide comprising a core toxin segment selected from the group consisting of (a) a polypeptide comprising the amino acid sequence of residues114 to 655 of SEQ ID NO:2: EAVVSKALSELEGLRNALEGYTSALEAWQNNRSDKLKQLLVYERFVSTENLFKFAMPSFRSVGFEGPLLTVYAQAANLHLFLLKNAELFGAEWGMQQYEIDLFYNEQKGYVEEYTDHCVKWYNEGLNKLKNASGVKGKVWENYNRFRREMTIMVLDLLPLFPIYDARTYPMETVTELTRQIFTDPIGLTGINETKYPDWYGAASSEFVLIENRAIPKPGLFQWLTKINVRARVVEPNDRFAIWTGHSVVTQYTKSTTENTFNYGTSSGSTLSHTFDLLSKDIYQTYSIAAANKSATWYQA VPLLRLYGINASNVLSEDAFSFSNDIPSSKCKSTYSSDQLPIELLDEPIYGDLEEYGHRLSYVSEIFKETGSGTIPVLGWTHVSVRPDNKLYPDKITQLPAVKSTPYPEVKGLNVEKGPGFTGGDLVKVTASGNTLVRLKVKTDSPGTQKYRIRLKYAATSNFYLGAYAGSSGNNGIPGISSVPKTMDIGEPLSYTSFAYIDLPSSYTFSQTEEILKFVVNVFDSGGAIYADRVEFIPVDAD; (b) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of residues 114 to 655 of SEQ ID NO:2; (c) a polypeptide comprising an amino acid sequence of residues 114 to 655 of SEQ ID NO:2 with up to 20 amino acid substitutions, deletions, or modifications that do not adversely affect expression or activity of the toxin encoded by SEQ ID NO:2; or an insecticidally active fragment thereof.
Patent NZ-602353-A (NZ)
Title: Peptide-lipid constructs and their use in diagnostic and therapeutic applications
Inventor: WEINBERG CRISTINA-SIMONA
IPC: A61K39/385
Filed: 2008-09-11
Abstract: Disclosed is a method of effecting qualitative and quantitative changes in the levels of a peptide expressed at the surface of cells including the step of contacting the cells with a solution of a peptide-lipid construct of the structure F-S-L at a concentration and for a time and temperature sufficient to allow the construct to incorporate into the surface, where F is the peptide, S is a spacer covalently linking F to L via an oligomer of ethylene glycol, and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids.
Patent NZ-615317-A (NZ)
Title: Electronic door lock with modular components
Inventor: SUMCAD GUSTAVO L
IPC: G07C9/00
Filed: 2009-06-08
Abstract: An electronic door lock mounts to a door and includes an inner side and an outer side. The electronic door lock is operable to control access to an access controlled area positioned adjacent the inner side of the door. The electronic door lock includes an outer base (146) connected to the outer side of the door, an inner base connected to the inner side of the door, a locking mechanism (180) coupled to the door and movable between a locked position and an unlocked position in response to a control signal, and a control circuit disposed within the inner base and operable to generate the control signal in response to an input credential. An attachment interface is at least partially formed as part of the outer base. An outer escutcheon (44) is supported by at least one of the outer base and the door, the outer escutcheon positioned to substantially cover the outer base and including an aperture positioned adjacent the attachment interface to expose the attachment interface. The outer base further includes an anti-tamper wall (170, 174) positioned between the outer escutcheon aperture and the locking mechanism to inhibit access to the locking mechanism from the outer escutcheon aperture. Each of a plurality of different types of credential readers (76) is selectively attachable and removable from the attachment interface when the outer base is attached to the door to electrically connect a selected one of the plurality of different types of credential readers to the control circuit to provide the input. A communication module is connected to the control circuit, and the communication module is operable to communicate with a device that is separate from the electronic door lock.
Patent NZ-628768-A (NZ)
Title: Process for preparing tiotropium bromide
Inventor: SOBRAL LUIS
IPC: C07D451/14
Filed: 2013-02-08
Abstract: The present disclosure relates to a novel process for the preparation of tiotropium bromide there is provided a process for preparing tiotropium bromide comprising (i) reacting scopine oxalate with diethylamine in an inert solvent to form scopine; (ii) reacting scopine and methyl di-(2-dithienyl)glycolate (MDTG) in the presence of an inorganic base, and in an inert solvent to form N-demethyltiotropium; (iii) reacting N-demethyltiotropium with bromomethane in an inert solvent to form tiotropium bromide; (iv) crystallizing tiotropium bromide in a mixture of methanol and acetone, and optionally thereafter, (v) micronizing the tiotropium bromide so formed.
Patent NZ-629297-A (NZ)
Title: Foreign exchange transaction apparatus, foreign exchange transaction system, transmission/reception method and program
Inventor: MIYASHIRO MEIGETSU
IPC: G06Q40/06
Filed: 2014-03-13
Abstract: Disclosed is a transmission/reception method for transmitting and receiving information corresponding to foreign exchange transactions of a plurality of currencies between an information processing apparatus having a control unit and the outside. The method includes the steps of: the control unit generating screen information for accepting selection of one currency from among a predetermined plurality of currencies and accepting a bundled order of transactions concerning each exchange of the selected one currency for the rest of the currencies other than the selected one currency. The control unit then transmits the generated screen information to the outside. The control unit then receives the order information for the bundled order from the outside.
Patent NZ-700771-A (NZ)
Title: Mechanical treatment of processed biomass
Inventor: MEDOFF MARSHALL
IPC: C12P7/06
Filed: 2011-02-11
Abstract: Disclosed herein is a method comprising: reducing the size of a cellulosic or lignocellulosic feedstock utilising an initial mechanical treatment, wherein the initial mechanical treatment is selected from the group consisting of cutting, milling, grinding, pressing, shearing and chopping; irradiating the cellulosic or lignocellulosic feedstock with ionizing radiation to produce a structurally modified cellulosic or lignocellulosic material; chemically treating the structurally modified material at ambient temperature; and mechanically treating the structurally modified material, wherein the mechanical treatment is selected from the group consisting of cutting, milling, pressing, grinding, shearing and chopping.
Patent NZ-704023-A (NZ)
Title: Novel rebamipide prodrug, method for producing same, and usage thereof
Inventor: CHO EUI-HWAN
IPC: C07D413/12
Filed: 2013-06-26
Abstract: The present invention relates to a novel rebamipide prodrug, a method for producing same, and usage thereof, and more specifically to a novel rebamipide prodrug, a method for producing same, and a pharmaceutical composition containing same as an active ingredient. The novel rebamipide prodrug according to the present invention has an absorption rate in the body approximately 25 times the absorption rate of rebamipide, and thus can be effectively used, in place of rebamipide, in preventing or treating gastric ulcer, acute and chronic gastritis, dry eye syndrome, cancer, degenerative joint disease, rheumatoid arthritis or obesity.
Patent NZ-706445-A (NZ)
Title: Anterior development and postural trainer
Inventor: HANG WILLIAM M
IPC: A61F5/56
Filed: 2015-03-27
Abstract: An orthodontic appliance that postures the lower jaw forward and connects the lower jaw to the upper jaw, comprising two upper palate bases, a labial bow located in a front region of the appliance, a lower incisor support wire located in a front region of the appliance, an upper incisor support wire located in the a front region of the appliance, a lateral incisor support wire, cuspid support wires located in a front region of the appliance, a palatal bar which connects the two bases of the appliance, and landing gear reminders to engage the soft tissue covering the mandible. The landing gear reminders can be folded up when they are not being used and include hydro-plastic ends for comfort when engaging the soft tissue covering the mandible.